Journal ArticleDOI
Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study
Reads0
Chats0
TLDR
The number of chronic myeloid leukemia (CML) patients in Germany is expected to increase further until at least 2040–2050 with a maximum of more than 20,000 CML patients as the most probable scenario.Abstract:
Purpose
Due to prolonged survival, there will be many more chronic myeloid leukemia (CML) patients alive in the future. The aims of this work were to estimate the current prevalence of CML by using routine data and to project future patient numbers in Germany.read more
Citations
More filters
Journal ArticleDOI
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
TL;DR: Higher out-of-pocket expense for TKI therapy is significantly associated with worse HRQoL in persons with chronic-phase CML in CCyR receiving TKI Therapy, indicating the importance of drug cost and health insurance policies on people’s HRQeL.
Journal ArticleDOI
Dasatinib dose management for the treatment of chronic myeloid leukemia.
TL;DR: Results obtained from dose optimization and discontinuation trials currently in progress will help practitioners determine the best dose and duration of dasatinib for patients with CML, because treatment decisions will be made through continued discussions between physicians and patients.
Journal ArticleDOI
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy
TL;DR: Social-economic and clinical variables were significantly associated with PROs in persons with CML receiving TKI-therapy and better well-being, and adverse impact on daily life and work was significant associated with more interests in TKIs and less impact on subject’s dailylife and work.
Journal ArticleDOI
Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.
TL;DR: It is concluded that dasatinib, similar to nilotinib, has the adverse impact on glucose-lipid metabolism compared with imatinib.
Book ChapterDOI
Epidemiology and Etiology of Chronic Myeloid Leukemia
Maren Rohrbacher,Joerg Hasford +1 more
TL;DR: The authors ask for further research on the occurrence of secondary malignancies, other therapy-related risks, treatment of elderly patients, economic impact on healthcare systems by the expensive long-term treatment, and chances to stop treatment with TKIs in patients with complete remission without risking relapse of CML.
References
More filters
Journal ArticleDOI
Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century
Dianne Pulte,Dianne Pulte,Benjamin Barnes,Lina Jansen,Nora Eisemann,Katharina Emrich,Adam Gondos,Stefan Hentschel,Bernd Holleczek,Klaus Kraywinkel,Hermann Brenner +10 more
TL;DR: Five-year survival estimates were higher in the US than in Germany overall, but the difference was only significant for ages 50–59 years, and strong improvement in survival was seen between 2002 and 2006.
Journal ArticleDOI
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
Lotta Ohm,Adam Lundqvist,Paul W. Dickman,Martin Höglund,Ulf Persson,Leif Stenke,Katarina Steen Carlsson,Magnus Björkholm +7 more
TL;DR: The authors' data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities, as well as a lifetime cost-effectiveness model developed.
Journal ArticleDOI
Chronic myelogenous leukaemia market.
TL;DR: Imatinib (Gleevec; Novartis), the first approved tyrosine kinase inhibitor (TKI), alters the natural course of CML, creating new niches in the CML market.
Journal ArticleDOI
The role of hematopoietic stem cell transplantation in chronic myeloid leukemia
TL;DR: A more balanced appraisal of HSCT for individual patients should include disease risk, transplant risk, and macroeconomic aspects and should be integrated into the treatment algorithms from diagnosis and be considered very early at first TKI failure for patients with high disease but low transplant risk.
Related Papers (5)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini,Laura Antolini,Franois Xavier Mahon,François Guilhot,Michael W. Deininger,Carmen Fava,Arnon Nagler,Chiara Maria Della Casa,Enrica Morra,Elisabetta Abruzzese,Anna D'Emilio,Fabio Stagno,Philipp le Coutre,Rafael Hurtado-Monroy,Valeria Santini,Bruno Martino,Fabrizio Pane,Andrea Piccin,P Giraldo,Sarit Assouline,Muheez A. Durosinmi,O. C. Leeksma,Enrico Pogliani,Miriam Puttini,Eun-Jung Jang,Josy Reiffers,Maria Grazia Valsecchi,Dong-Wook Kim +27 more
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more